$BIOT News
Last published 2mo ago
- 2mo agoBIOTINSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development InitiativesGlobeNewswireNEW YORK and TOKYO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ:BIOT) ("Instinct Bio" or the "Company") today provided an operational update on the
- 3mo agoBIOTInstinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in IndonesiaGlobeNewswireNEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ:BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARVA
- 3mo agoBIOTBIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics MarketsGlobeNewswireNEW YORK and TOKYO, July 29, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ:BIOT) ("Instinct Bio" or the "Company") today announced its decision to bring its own Japanese
- 3y agoBIOTBIOTUBiotech Acquisition Company Announces LiquidationGlobeNewswireNew York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete
- 3y agoBIOTBiotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension AmendmentPR NewswireNEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed
- 4y agoBIOTBlade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology ConferenceBusiness WireBlade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the "Drug
- 4y agoBIOTBiotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination AgreementPR NewswireNEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blad
- 4y agoBIOTBiotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business CombinationPR NewswireExtraordinary General Meeting of BAC's shareholders postponed until a to-be-determined later date NEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpo
- 4y agoBIOTBiotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business CombinationPR NewswireExtraordinary General Meeting of BAC's shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern Time NEW YORK and SOUTH SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special p
- 4y agoBIOTBiotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.PR NewswireNEW YORK, May 24, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a submission to the United States
- 4y agoBIOTBlade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International ConferenceBusiness WireCudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model Non-competitive autotaxin inhibition by cudetaxestat maintained potency in the presence of elevated substrate concentrations found i
- 4y agoBIOTBlade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International ConferenceBusiness WireNo significant drug-drug interaction (DDI) seen with cudetaxestat in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF) Cudetaxestat was well tolerated and showed no reports of treatme
- 4y agoBIOTBiotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity FacilityPR NewswireExtraordinary General Meeting of BAC's shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed "Blade Biotherapeutics, Inc." upon Business Combination closing, with common stock and warrants expected
- 4y agoBIOTBiotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.PR NewswireNEW YORK, April 4, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securitie
- 4y agoBIOTBlade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data PackageBusiness WireU.S. Food and Drug Administration (FDA) provides feedback necessary to proceed into a phase 2 proof of concept (PoC)/dose ranging study of cudetaxestat in patients with idiopathic pulmonary fibrosis (IPF) Company plans to advance cudetaxestat,
- 4y agoBIOTBlade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International ConferenceBusiness WireCompany to present three posters with data for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for idiopathic pulmonary fibrosis (IPF) New data from a phase 1 drug-drug interaction clinical study of cud
- 4y agoBIOTCPTKDSACVGIIMoore Kuehn Encourages BIOT, VGII, CPTK, and DSAC Investors to Contact Law FirmGlobeNewswireNEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair
- 4y agoBIOTBlade Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireBlade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will present at two investor conf
- 4y agoBIOTBlade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary FibrosisBusiness WireClinical study found that cudetaxestat, a non-competitive inhibitor of autotaxin, was well tolerated and showed no reports of drug-related serious adverse events or discontinuations when co-administered with either pirfenidone or nintedanib Submis
- 4y agoBIOTBiotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.PR NewswireNEW YORK, Jan. 3, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential submission to the U
- 4y agoBIOTBlade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary FibrosisBusiness WirePhase 1 study assessed the effect of cudetaxestat on the pharmacokinetics of a combination of probe substrates for CYP450 enzymes Company on track to initiate planned phase 2 clinical study of cudetaxestat in idiopathic pulmonary fibrosis (IPF) in
- 4y agoAMGNBIOTFGENBlade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical DevelopmentBusiness WireBlade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president
- 5y agoBIOTDSACMNRZIXIMoore Kuehn Encourages MNR, DSAC, BIOT, and ZIXI Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 5y agoBIOTBiotech Acquisition Company and Blade Therapeutics Announce Definitive Merger AgreementPR NewswireNEW YORK and SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Proposed merger to create publicly traded biopharmaceutica
- 5y agoBIOTBiotech Acquisition Company Announces Closing of $230,000,000 Initial Public OfferingGlobeNewswireNew York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the “Company”) announced today that it has closed its initial public offering of 23,000,000 units, including 3,000,000...
- 5y agoBIOTBiotech Acquisition Company Announces Pricing of $200 Million Initial Public OfferingGlobeNewswireNew York, NY, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset...